^
Association details:
| Biomarker: | HLA-A*02:01 |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Published date:
03/02/2023
Excerpt:
Pts with solid tumors included in early clinical trials who require germline HLA testing in VHIO's Early Drug Development Unit were included in the analysis from December 2021 to November 2022....Association between HLA A02:01 and response to immunotherapy was found significant (p-value 0.0156).
